Correlation Between Seres Therapeutics and Crispr Therapeutics
Can any of the company-specific risk be diversified away by investing in both Seres Therapeutics and Crispr Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Seres Therapeutics and Crispr Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Seres Therapeutics and Crispr Therapeutics AG, you can compare the effects of market volatilities on Seres Therapeutics and Crispr Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Seres Therapeutics with a short position of Crispr Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Seres Therapeutics and Crispr Therapeutics.
Diversification Opportunities for Seres Therapeutics and Crispr Therapeutics
0.88 | Correlation Coefficient |
Very poor diversification
The 3 months correlation between Seres and Crispr is 0.88. Overlapping area represents the amount of risk that can be diversified away by holding Seres Therapeutics and Crispr Therapeutics AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Crispr Therapeutics and Seres Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Seres Therapeutics are associated (or correlated) with Crispr Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Crispr Therapeutics has no effect on the direction of Seres Therapeutics i.e., Seres Therapeutics and Crispr Therapeutics go up and down completely randomly.
Pair Corralation between Seres Therapeutics and Crispr Therapeutics
Given the investment horizon of 90 days Seres Therapeutics is expected to generate 1.69 times more return on investment than Crispr Therapeutics. However, Seres Therapeutics is 1.69 times more volatile than Crispr Therapeutics AG. It trades about 0.12 of its potential returns per unit of risk. Crispr Therapeutics AG is currently generating about 0.18 per unit of risk. If you would invest 963.00 in Seres Therapeutics on May 2, 2025 and sell it today you would earn a total of 477.00 from holding Seres Therapeutics or generate 49.53% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Strong |
Accuracy | 100.0% |
Values | Daily Returns |
Seres Therapeutics vs. Crispr Therapeutics AG
Performance |
Timeline |
Seres Therapeutics |
Crispr Therapeutics |
Seres Therapeutics and Crispr Therapeutics Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Seres Therapeutics and Crispr Therapeutics
The main advantage of trading using opposite Seres Therapeutics and Crispr Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Seres Therapeutics position performs unexpectedly, Crispr Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Crispr Therapeutics will offset losses from the drop in Crispr Therapeutics' long position.Seres Therapeutics vs. Fate Therapeutics | Seres Therapeutics vs. Iovance Biotherapeutics | Seres Therapeutics vs. Veracyte |
Crispr Therapeutics vs. Intellia Therapeutics | Crispr Therapeutics vs. Editas Medicine | Crispr Therapeutics vs. Vertex Pharmaceuticals | Crispr Therapeutics vs. Beam Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Complementary Tools
CEOs Directory Screen CEOs from public companies around the world | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |